Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Box Inc (BOX) vs Eli Lilly And Co (LLY) Price & Performance

Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Box Inc vs Eli Lilly And Co — how do they compare? Box Inc trades at $32.86 (market cap $4.65B), while Eli Lilly And Co trades at $1,216.26 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 236.6× Box Inc's market cap, and Eli Lilly And Co pays a 0.56% dividend while Box Inc pays none. Which is the better fit depends on your goals.

BOXLLY
Market Cap
$4.65B$1.10T
Sector
TechnologyHealth
52-Week High
$33.60$1.24K
52-Week Low
$21.37$635.22
Enterprise Value
$5.21B$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Box Inc

BOX Inc. (NYSE: BOX) trades at $33.24, up 4.36% today, showing strong momentum near resistance levels. The company delivered solid Q1 2026 earnings beat with EPS of $0.37 versus $0.36 expected, continuing positive earnings surprises. Revenue growth accelerated to $1.09 billion in 2025 with net income margin expanding to 22.43%. Technical indicators show bullish momentum with the stock trading above key support levels and moving averages signaling strength.

BOX presents growth potential with strong revenue expansion and improving profitability, supported by recent enterprise contract wins like Quintas Energy's AI platform selection. However, elevated P/E ratio of 51.94 suggests premium valuation, while negative equity and high debt levels warrant monitoring. Analyst consensus remains bullish with $37 price target, representing 11% upside from current levels.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Box Inc

Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.

Read more on BOX

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY